<DOC>
	<DOC>NCT01669902</DOC>
	<brief_summary>This multicenter observational study will evaluate the use of RoActemra/Actemra (tocilizumab) in monotherapy in patients with active moderate to severe rheumatoid arthritis unable to use methotrexate. Eligible patients initiated on RoActemra/Actemra treatment will be followed for 6 months.</brief_summary>
	<brief_title>An Observational Study of RoActemra/Actemra (Tocilizumab) in Monotherapy in Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Moderate to severe rheumatoid arthritis according to the revised (1987) ACR criteria Patients who for any reason do not take methotrexate and for whom the treating physician has made a decision to prescribe RoActemra/Actemra as monotherapy; patients who commenced RoActemra/Actemra as monotherapy within 8 weeks prior to the enrolment visit may be included Concomitant treatment with nonsteroidal antiinflammatory drug (NSAID) or corticosteroids (orally or intraarticularly) is allowed Patients who have received RoActemra/Actemra more than 8 weeks prior to enrolment visit Previous RoActemra/Actemra treatment in a clinical trial or for compassionate use Concomitant DMARD treatment for rheumatoid arthritis (e.g. hyroxychloroquine, sulfasalazine, methotrexate, leflunomide, gold compounds, cyclosporine) Treatment with any investigational agent within 4 weeks (or 5 halflives of investigational agent, whichever is longer) before starting RoActemra/Actemra treatment History of autoimmune disease or any joint inflammatory disease other than rheumatoid arthritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>